À propos de ce podcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
270 épisodes · Levenswetenschappen
BioSpace
Dernier épisodeThe decisions behind scientific progress
À propos de ce podcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Épisodes récents
- J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback14 oct. · 20 min
- Beyond equity: Why venture debt is reshaping European biotech8 oct. · 23 min
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more7 oct. · 24 min
- The race for access: How the FAIR Act could reclaim U.S. biotech leadership1 oct. · 20 min
- AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll30 sept. · 20 min
- How radioligand therapy is rewriting cancer care24 sept. · 16 min
- Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz23 sept. · 21 min
- When vision fades: Rethinking wet AMD and the durability gap17 sept. · 22 min
- FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival16 sept. · 22 min
- Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease9 sept. · 20 min
sharemy.show/fr/biospace
Pour une affiche ou une diapo.